Gastrointestinal stromal tumors and second primary malignancies: a retrospective monocentric analysis

In the post-Imatinib era, the median survival of patients diagnosed with GIST has reached almost 5 years. Prolonging GIST-specific survival, GIST patients have an increased incidence of secondary neoplasia. Data on the prognostic impact of second tumors in GIST patients are very poor with few and sm...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neoplasma 2020-11, Vol.67 (6), p.1416-1423
Hauptverfasser:	Comandini, D, Grassi, M, Prelaj, A, Martelli, V, Damiani, A, Damiano, G, Rebuzzi, S Elena
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Gastrointestinal Neoplasms - epidemiology Gastrointestinal Neoplasms - genetics Gastrointestinal Stromal Tumors - drug therapy Gastrointestinal Stromal Tumors - epidemiology Gastrointestinal Stromal Tumors - genetics Humans Imatinib Mesylate - therapeutic use Neoplasms, Second Primary - epidemiology Neoplasms, Second Primary - genetics Prognosis Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!